Mankind Pharma: Inside the Chronic Growth Segment and Premium Valuations
India’s fifth-largest drugmaker is thriving in diabetes and cardiac care while waiting for its infection-treatment business to recover Mankind Pharma is executing a textbook transition from acute to chronic therapies, and the third-quarter numbers prove the strategy is working—mostly. The company posted 11.5% revenue growth to Rs 35,672 million, beating estimates, while margins expanded to … Read more